Leader in Business Outcomes Provides Program to Help Pharmaceutical Developers and Contract Research Organizations Save Costs, Reduce Cycle Times
FREMONT, Calif., June 25, 2012 (GLOBE NEWSWIRE) -- iGATE, the first integrated technology and operations company providing Business Outcomes-based solutions, today announced the iGATE Research Accelerator platform for Life Sciences, a streamlined program designed to reduce the cycle times and costs of bringing a new drug or medical device to market.
The Research Accelerator (RA) empowers pharmaceutical developers and contract research organizations (CROs) with fully integrated clinical information management technology and iGATE's business outcomes-based methodology, enabling them to make better, faster, more informed decisions throughout the drug development process. Drug developers that engage in a business outcomes approach pay only for performance, unlike the time and material billing other vendors use, leading to increased project hours and ultimately, higher billing.
"The pressures on life science companies to bring compounds to market quickly and effectively are more acute than ever before, and the slightest inefficiencies can put millions of dollars at risk," said David Kruzner, executive vice president, iTOPS Solutions and Consulting, with iGATE.
"Utilizing the RA platform, organizations can do a far better job of capturing critical data across multiple systems and verifying, analyzing, reporting and reusing it through multiple phases, supporting their short-term and long-term objectives."
iGATE's end-to-end management solution for R&D data links the systems and data-related procedures through every phase of the clinical process -- from data capture to clinical data management, product registrations, document and submission management, pharma co-vigilence risk management, reporting and analytics, and clinical operations R&D portfolio management.
By providing a single source of truth for clinical development information, iGATE's RA offers the potential for a wide range of benefits, including the following:
iGATE's Business Outcomes model provides BPO and IT services as an integrated offering, with payments based on a specified business outcome. The "pay for results only" formula enables customers to scale up and scale down based on business cycles, reduce technology risks, receive predictable results, benefit from a variable costs structure and eliminate management headaches from managing the outsourcing relationships.
iGATE will exhibit its life sciences industry solutions exhibit at the DIA conference at Booth #3344.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.